Below is an excerpt from the balance sheet of Greene Plc. Greene reports under IFRS. (million £) 2019 2020 Capitalized R&D asset 1,200 1,500 During fiscal year 2020, Greene spent £700 million in cash on research and development. Out of these £700 million, £250 million were spent researching a new drug, whose technological and commercial feasibility has not yet been established. The remaining £450 million were development costs, relating to another drug for which technological and commercial feasibility has been established. 

What was the total amount of expenses related to the firm's research and development activities during fiscal year 2020?